Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCR-ABL1 F317V
i
Other names:
BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
25
;
613
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older (NCT02494882)
Phase 1
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
07/27/2023
Initiation :
06/29/2015
Primary completion :
06/01/2025
Completion :
06/01/2025
ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP
|
BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R
|
dasatinib • Jakafi (ruxolitinib) • dexamethasone
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login